Literature DB >> 22138309

Synthesis and biological evaluation of cyclopentane-linked alkyl phosphocholines as potential anticancer agents that act by inhibiting Akt phosphorylation.

Md Maqusood Alam1, Eun-Ha Joh, Yuri Kim, Yeon Il Oh, Jongki Hong, Baek Kim, Dong-Hyun Kim, Yong Sup Lee.   

Abstract

Three new series of novel alkylphosphocholine (APC) derivatives containing a cyclopentane ring near the phosphocholine head group were synthesized. In the first set of analogues, the phosphocholine head group was attached to the secondary alcohol of trans-2-(hydroxymethyl)cyclopentanol, whereas in the second and third sets of analogues, the phosphocholine head group was linked to the primary alcohol of trans- and cis-2-(hydroxymethyl)cyclopentanol, respectively. Of the compounds synthesized, compound 6d most potently inhibited Akt phosphorylation with an IC(50) value of 3.6 μM, its potency was greater than the reference compounds miltefosine, perifosine, and erufosine. Compounds 6b and 6d exhibited the most potent growth-inhibitory effects on A549, MCF-7, and KATO-III human cancer cell lines. These compounds also showed more active anti-proliferative effects than the reference compounds. Importantly, the cytotoxic effects of these compounds on A549 cell line were proportional to their abilities to inhibit Akt phosphorylation, which supports that these synthesized APC compounds are novel inhibitors of the Akt cell survival pathway.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138309     DOI: 10.1016/j.ejmech.2011.11.018

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells.

Authors:  Carsten Pelz; Sonja Häckel; Geo Semini; Sandra Schrötter; Willem Bintig; Sebastian Stricker; Gudrun Mrawietz; Andreas Klein; Lothar Lucka; Vadim Shmanai; Britta Eickholt; Annette Hildmann; Kerstin Danker
Journal:  Cell Oncol (Dordr)       Date:  2018-07-25       Impact factor: 6.730

2.  The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

Authors:  Sarit Assouline; Eftihia Cocolakis; Katherine L B Borden
Journal:  Cancers (Basel)       Date:  2012-11-02       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.